Resistance of tumours to taxanes causes chemotherapy failure in numerous patients. Resistance is partly due to the low tumour uptake of taxanes and their rapid metabolism. Structural modifications of taxanes can reduce their P-glycoprotein-related efflux or decrease metabolism and consequently increase taxane efficiency. This study compared cytotoxicity and effects of the cell cycle, transport and metabolism of novel taxanes SB-T-1102, SB-T-1103, SB-T-1214 and SB-T-1216, fluorinated SB-T-12851, SB-T-12852, SB-T-12853, SB-T-12854 and IDN5109 with paclitaxel in paclitaxel-sensitive (MDA-MB-435) and paclitaxel-resistant (NCI/ADR-RES) human cancer cells. We have shown before that NCI/ADR-RES cells were 1,000-fold less sensitive to paclitaxel than MDA-MB-435 cells in correspondence to P-glycoprotein overexpression and up to 20-fold lower uptake of the drug in the resistant cells. The uptake of novel taxanes was 1.2 to 3.8 times lower than that of paclitaxel in the MDA-MB-435 cells, but 1.5 to 6.5 times higher in NCI/ADR-RES cells. NCI/ADR-RES cells were correspondingly only 2- to 6.6-fold less sensitive than the MDA-MB-435 cells to novel taxanes. Both cell lines showed minimal metabolism of the novel taxanes which was therefore not responsible for their different sensitivity, the observed differences in their individual efficiency and higher effects than paclitaxel. All novel taxanes caused G(2)/M block of the cell cycle similar to paclitaxel, but lower at concentrations by order of magnitude. Thus, structural modifications of taxanes resulting in their decreased P-glycoprotein-related transport probably caused their higher efficiency than paclitaxel in multidrug-resistant NCI/ADR-RES tumour cells.

Toxicogenomics Group National Institute of Public Health Srobarova 48 100 42 Prague 10 Czech Republic

Zobrazit více v PubMed

Chem Rec. 2001;1(3):195-211 PubMed

Xenobiotica. 2006 Sep;36(9):772-92 PubMed

Annu Rev Med. 1997;48:353-74 PubMed

Biochemistry. 1981 May 26;20(11):3247-52 PubMed

J Chem Inf Model. 2009 Feb;49(2):424-36 PubMed

Oncogene. 2001 Aug 16;20(36):4995-5004 PubMed

Br J Cancer. 2000 Dec;83(12):1762-8 PubMed

ChemMedChem. 2007 Jul;2(7):920-42 PubMed

J Med Chem. 1996 Sep 27;39(20):3889-96 PubMed

Naunyn Schmiedebergs Arch Pharmacol. 2005 Jul;372(1):95-105 PubMed

Anticancer Res. 2009 Aug;29(8):2951-60 PubMed

Arch Toxicol. 2000 Oct;74(8):437-46 PubMed

Invest New Drugs. 2011 Jun;29(3):411-23 PubMed

Pharmacogenet Genomics. 2008 Mar;18(3):263-73 PubMed

J Chromatogr B Biomed Sci Appl. 2000 Oct 10;748(2):383-8 PubMed

Mol Pharmacol. 2003 Mar;63(3):766-72 PubMed

Semin Oncol. 2008 Apr;35(2 Suppl 2):S1-S14; quiz S39 PubMed

Crit Rev Oncol Hematol. 2001 Mar;37(3):237-47 PubMed

Cancer Chemother Biol Response Modif. 1997;17:59-79 PubMed

Naunyn Schmiedebergs Arch Pharmacol. 2003 Sep;368(3):200-9 PubMed

Third-generation taxanes SB-T-121605 and SB-T-121606 are effective in pancreatic ductal adenocarcinoma

Anticancer regimens containing third generation taxanes SB-T-121605 and SB-T-121606 are highly effective in resistant ovarian carcinoma model

The Role of TRIP6, ABCC3 and CPS1 Expression in Resistance of Ovarian Cancer to Taxanes

Upregulation of vitamin D-binding protein is associated with changes in insulin production in pancreatic beta-cells exposed to p,p'-DDT and p,p'-DDE